NCT07489352
N-of-1 Trial to Promote Beta-Blocker Titration in Heart Failure
At risk: Primary completion moved 6 months later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Mar 5, 2027 to Sep 5, 2027
- Study completion pushed from Mar 5, 2027 to Oct 5, 2027
- Notable Primary endpoint(s) modified
- Eligibility criteria expanded, about 94 words
- Secondary endpoint revised
- Site details revised
- Notable Enrolling by invitation only
- Study sites: 0 to 1
- Start date changed from estimate of Sep 5, 2026 to Jul 31, 2026
- Notable Start date: May 5, 2026 to Sep 5, 2026v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (1)
Arms and interventions
N-of-1 trials using a crossover withdrawal/reversal design will allow for 1-5 three-week periods as needed to identify the highest tolerated beta-blocker dose
We will compare the intervention to an "enhanced usual care." Our study team will not provide guidance for dose titration (this will be at physician and patient discretion); and participants will not have access to PROs or the data visualization tool. Since attention can affect outcomes, we will "enhance usual care" by conducting phone calls at the same frequency as the intervention group.
Behavioral: N-of-1 trials, Enhanced usual care
Sites
1 site in 1 country
- New York Presbyterian Hospital/Weill Medical College of Cornell UniversityNew York, New York, United States